⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Bright Peak Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Bright Peak Therapeutics
↗Allschwil, Switzerland
Bright Peak Therapeutics is a clinical-stage biotechnology company dedicated to creating next-generation cytokine immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages a proprietary chemical protein synthesis and conjugation platform to engineer multifunctional immunotherapies that allow for tissue and cell-specific targeting, aiming to enhance efficacy while minimizing systemic side effects.
Headquartered in Basel, Switzerland, with additional operations in San Diego, USA, the company is backed by prominent healthcare investors. Bright Peak's pipeline focuses on novel designer immunotherapies, including its lead program, BPT567, a first-in-class PD1-IL18 immunoconjugate designed for the treatment of solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$197M
Investors:Johnson & Johnson Innovation – JJDC, Versant Ventures, Venrock, KB Investment, Northleaf Capital Partners, Fidelity Management & Research Company, RA Capital Management, Qatar Investment Authority, Invus, Alexandria Venture Investments
PIPELINE
Stage:Phase 1/2a
Lead Drug Stage:Phase 1/2a
Modalities:Immunocytokines, Protein engineering, Immunoconjugates
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Ajinomoto (collaboration for AJICAP site-specific bioconjugation technology), Livzon Pharmaceutical Group (licensing of anti-PD-1 antibody)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Fredrik Wiklund - CEO
Scientific Founders:Jeffrey Bode
LINKS
Website:brightpeaktx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bright Peak Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.